ArticleInfection and drug resistance2026
Clinical and Microbiological Characteristics and Antimicrobial Susceptibility Patterns of Multidrug-Resistant
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Patients in intensive care units are at risk of infections caused by multidrug-resistant (MDR) pathogens, including the opportunistic bacterium Methods: In this retrospective single-center study, 70 patients hospitalized in a tertiary care center in Türkiye between 2017 and 2023 who met criteria for true infection were included, although Results: The isolates demonstrated high levels of resistance to most conventional antibiotics tested. Tigecycline showed the highest in vitro susceptibility rate, with 95.2% of isolates classified as susceptible. Tigecycline was also the most frequently used antimicrobial agent in clinical management, with a mean treatment duration of 10.3 days. The mean patient age was 72.7 years, and tigecycline treatment was administered to 88.5% of the patients. Most infections involved the urinary tract, while one patient developed invasive disease with concurrent bacteremia and pneumonia. Conclusion: MDR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.